Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323800 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma to Stem Coronavirus (CSSC-001)
A Phase 2 study of Coronavirus and Convalescence, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT04323800: Completed Phase 2 study of Coronavirus and Convalescence, sponsored by Johns Hopkins University.
NCT04323800 is a Phase 2 study of Coronavirus and Convalescence that has completed, run by Johns Hopkins University. The registered enrollment target is 180 participants, below the 1,396-participant average among 20 other Coronavirus trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04323800, a Phase 2 study of Coronavirus and Convalescence, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
Primary Outcome
Comparison of proportions of cumulative incidence of development of SARS-Cov-2 infection (symptoms compatible with infection and/or + molecular testing) regardless of disease severity, following high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19.
Conditions Studied
Interventions
- BIOLOGICAL Anti- SARS-CoV-2 Plasma
- BIOLOGICAL SARS-CoV-2 non-immune Plasma
Study Locations (20)
California
- University of California, San Diego - La Jolla
- University of California, Los Angeles - Los Angeles
- University of California, Irvine Health - Orange
New Mexico
- University of New Mexico Health Sciences Center - Albuquerque
- Center for American Indian Health - Gallup Office - Gallup
- Center for American Indian Health - Shiprock Office - Shiprock
Connecticut
- Western Connecticut Health Network, Danbury Hospital - Danbury
- Western Connecticut Health Netowrk, Norwalk Hospital - Norwalk
Florida
- University of Miami - Coral Gables
- University of Miami Clinical Translational Research Site - Miami
Maryland
- Anne Arundel Medical Center - Annapolis
- The Johns Hopkins University - Baltimore
New York
- Vassar Brothers Medical Center - Poughkeepsie
- University of Rochester - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Center for American Indian Health - Whiteriver Office - Whiteriver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-06-10 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 2 |
What the finished NCT04323800 record still lists
NCT04323800 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,396-participant average among 20 other Coronavirus trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Coronavirus appearing as the primary indexed condition, and to 2 interventions - of which Anti- SARS-CoV-2 Plasma is the first listed.
NCT04323800 names 20 study sites across 12 states, led by California, New Mexico, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04323800 about?
NCT04323800 is a clinical study titled "Convalescent Plasma to Stem Coronavirus (CSSC-001)". Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
What is the current status of trial NCT04323800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2020-06-10. Estimated completion is 2021-06-22.
What conditions does trial NCT04323800 study?
This clinical trial studies the following conditions: Coronavirus, Convalescence.
What interventions are being tested in trial NCT04323800?
The interventions under investigation include: Anti- SARS-CoV-2 Plasma (BIOLOGICAL), SARS-CoV-2 non-immune Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04323800?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04323800 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04323800's enrollment target sits among peer trials
180 15th of 20 higher than 6 of 20 other Coronavirus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronavirus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
COMPLETED · Phase 2
-
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
COMPLETED · Phase 2
-
Convalescent Plasma in the Treatment of COVID 19
COMPLETED · Phase 2
-
University of Utah COVID-19 Hydrochloroquine Trial
COMPLETED · Phase 2
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI